Gout drug tapering trial: could patients finally take less medicine?
NCT ID NCT06622603
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether people with well-controlled gout (for at least 5 years) can safely reduce or stop their daily febuxostat. Fifty-nine adults will be split into three groups: one that lowers the dose, one that stops for 6 months then restarts a lower dose, and one that stays on their usual treatment. Researchers will track uric acid levels and any symptom return over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
febuxostat
What this could lead to
If successful, this could show that some gout patients can safely lower their medication dose without flare-ups, simplifying long-term management.
What could go wrong
This is a small, early-phase trial with only 59 participants. Results may not apply to all gout patients, and reducing medication could still cause symptom return or high uric acid levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 463-707, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••